Clinical Trial Update: All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing belantamab mafodotin plus pomalidomide and dexamethasone versus bortezomib plus pomalidomide and dexamethasone in relapsed/refractory …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Blenrep (belantamab mafodotin)
• DEXAMETHASONE (Dexamethasone)
• Pomalyst (pomalidomide)
• Velcade (bortezomib)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Multiple Myeloma | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-06-11